CME: Attention Deficit Hyperactivity Disorder (ADHD) in Adults: Updates from APA 2019
ACCREDITATION EXPIRED: October 01, 2021
Activity Description / Statement of Need:
In this online CME self-learning activity:
ADHD is a common neuropsychiatric disorder, affecting more than 2-3% of adults in the United States. ADHD is characterized by inattentive and/or hyperactive symptoms. Inattentive symptoms include inattention, distractibility and procrastination whereas hyperactive symptoms include impatience, restlessness, and impulsiveness. The presence of the disorder has a significant impact on health, education, and family situations.
The stimulant drug class presently represents first-line pharmacotherapy. There had previously been concern about the health risks of pharmacotherapy. However, time has brought additional experience with the medication, as ADHD medication use has risen by over 35% overall recently and over 53% in adults. Aside from experience, while simulants increase surrogate markers of heart rate and blood pressure by approximately 10 increments, there does not appear to be an increased risk of a serious adverse cardiovascular events. Another concern in recent years that may have been addressed is prescription drug abuse in children and young adults; research is now finding a significant gap between perceptions of abuse of ADHD stimulant medications and actual rates of misuse and abuse.
This activity is intended to be a one-hour learning activity focused on ADHD and its complications, designed to bring healthcare providers up to date in their practice and give them a sense of coming changes to practice and the literature.
Target Audience:
The following healthcare professionals: psychiatrists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in psychiatry; and any other healthcare professionals with an interest in or who clinically encounter pediatric patients with ADHD.
Commercial Support Disclosure: This program is supported by an educational grant from Shire Pharmaceuticals.
Learners may participate in this activity free of charge.
Release Date: October 01, 2019 -- Expiration Date: October 01, 2021
Faculty: Michael Enenbach, MD
Agenda
|
- Faculty member introduction, disclosures, overview of ADHD in adults |
|
- Major findings from APA 2019, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content) |
|
- Predicted of applicability to clinical practice and patient cases, where relevant |
|
- Concluding remarks |
Learning Objectives
By the end of the session the participant will be able to:
- Summarize the most impactful findings presented at the APA 2019 meeting relating to ADHD in adults related to disease diagnosis and apply them to patient cases.
- Summarize the most impactful findings presented at the APA 2019 meeting relating to ADHD in adults related to evaluation of degree therapeutic success and apply them to patient cases.
- Summarize the most impactful findings presented at the APA 2019 meeting relating to ADHD in adults related to emerging therapies and apply them to patient cases.
- Summarize the most impactful findings presented at the APA 2019 meeting relating to ADHD in adults related to quantifying benefit and risk of disease progression and apply them to patient cases.
Accreditation
ACCME Activity #201349376
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Michael Enenbach, MD , Associate Clinical Professor, UCLA, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents: Updates from APA 2019
Updates in the management of insomnia: Therapeutic updates and optimizing treatment
Bipolar and mood disorder: Therapeutic updates and best practices